David Wohl, MD, commented on new FDA criteria by which patients should be considered high-risk for severe COVID-19, expanding the pool of patients who can receive antibody treatment. In a , Wohl said as many as 75% of adults in the US could qualify for treatment under the new criteria.
“With the criteria expanded, we have so many more people who are eligible, at the same time we’re having a surge,” he said.
.